康方生物:盘中涨超 13% 临床研究获成果

和讯网
23 Apr

【康方生物盘中涨超 13%,高见 100 港元创历史新高】4 月 23 日,康方生物宣布,全球首创双特异性抗体新药依沃西单抗注射液联合化疗对比替雷利珠单抗联合化疗一线治疗晚期鳞状非小细胞肺癌的注册性 III 期临床研究,经独立数据监察委员会评估的预先设定的期中分析显示强阳性结果。本次三期临床,AK112 达到无进展生存期的主要研究终点,研究结果具有统计学显著获益和重大临床获益。本研究详细数据将在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10